BioSpace News Archive

myCare Studies Show Cellworks Multi-omics Biosimulation is a Superior Predictor of Complete Response to Therapies

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, today reported an update on the status of COVID-19 infected patients treated with PLX cells under a compassionate use program in Israel and the FDA Single Patient Expanded Access Program in the U.S. All treated patients were in Intensive Care Units (ICU),

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Virtual Healthcare Conference on Wednesday, May 20, 2020 . Michael Severino , M.D., vice chairman and president and Robert A. Michael , executive vice president and chief financial officer, will present at 9:50 a.m. Central time

Isofol Medical AB’s Board of Directors resolved on May 7, 2020, on a fully guaranteed new share issue of a maximum of 42,739,736 shares with preferential rights for the Company’s existing shareholders.

First-of-its-kind commercial solution analyzes 3D and sub-surface data 15,000 times faster than a typical Ga-FIB

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infections, announced today that it will present data on AGEN1181 at the American Society of Clinical Oncology (ASCO) upcoming ASCO2020 Virtual Scientific Program to be held May 29-31, 2020 .

Agreement Will Enable MYOS to Significantly Expand the Reach of its Veterinary Business

GI Supply announced the launch of the Piranha LC Aspiration Catheter for the improved suction of necrotic tissue and pancreatic blood fluids for the management of necrotizing pancreatitis for Endoscopic transmural necrosectomy.

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the international patent application titled “Methods for Treating Alzheimer’s Disease” was published as International Publication Number: WO 2020/092107 Al . The patent application describes treating

52-Week Post Hoc Analysis Shows Vibegron Patients Had Statistically Significant, Sustained Reduction in UUI and Total Incontinence Episodes Compared to Active Control IRVINE, Calif. & BASEL, Switzerland--( BUSINESS WIRE )-- Urovant Sciences (Nasdaq: UROV) announced today that data from the vibegron EMPOWUR 52-week extension study ( NCT03583372 ) and data by age groups from the 12-week placebo-controlled EMPOWUR study ( NCT03492281 ) will be pr